<a href="https://www.fiercebiotech.com/biotech/rebranded-belgian-biotech-lands-125m-rescued-galapagos-drug-candidates" hreflang="en">Rebranded Belgian biotech lands $125M for rescued Galapagos drug candidates</a>
Coultreon Biopharma, a rebranded Belgian biotech company, has secured $125 million in Series A funding to advance its drug candidates, including COL-5671 for autoimmune diseases, originally developed by Galapagos. The financing will help progress their pipeline, which also targets various cancers, amid a restructuring period for Galapagos.
Coultreon Biopharma's successful $125 million Series A fundraising, led by top-tier investors like Sofinnova and Forbion, highlights the growing investor interest in SIK3 inhibitors as a novel treatment for autoimmune diseases. This funding will accelerate the progression of their leading candidate, COL-5671, from phase 1 to phase 2 trials, aiming for a proof-of-concept data readout next year. As an expert in healthtech and biotech, monitoring Coultreon's progress could offer insights into emerging opportunities in autoimmune therapeutics and the potential for SIK3 inhibitors to fill existing treatment gaps.